Soligenix Inc SNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.35
- Day Range
- $0.36–0.37
- 52-Week Range
- $0.28–1.70
- Bid/Ask
- $0.36 / $0.37
- Shares Outstanding
- 21.77M
- Market Cap
- $7.84M
- Volume/Avg
- 58,835 / 220,119
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.soligenix.com
Valuation
|
Metric
|
SNGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SNGX
|
|---|---|
Quick Ratio | 2.67 |
Current Ratio | 2.77 |
Interest Coverage | — |
Quick Ratio
SNGX
Profitability
|
Metric
|
SNGX
|
|---|---|
Return on Assets (Normalized) | −109.56% |
Return on Equity (Normalized) | −195.83% |
Return on Invested Capital (Normalized) | −187.05% |
Return on Assets
SNGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?$@<Vh | LOCK|%zRk | $133B | |||
| Moderna Inc
MRNA
| LOCK|?fn%&l^ | LOCK|<> | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W@yZwX | LOCK|G&@> | $83B | |||
| argenx SE ADR
ARGX
| LOCK|q<Ths> | LOCK|lL | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#&g^j< | LOCK|nn | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|z&<vkSv | LOCK|Hg&w? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|FJD@J?d | LOCK|^n>&f | $28B | |||
| Incyte Corp
INCY
| LOCK|d#^@XdM | LOCK|$bP | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|K>#fG&J | LOCK|VfV | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&k#k<j | LOCK|cq | $14B |
United States